MSMudit Sabharwal

Mudit Sabharwal

*This is an algorithmically generated author record based on publicly available information.

Mudit Sabharwal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes: Prospective Observational Cohort Study

    by Banshi Saboo, Mudit Sabharwal, Mihir Gharia, Devina Aswal, Parth Modi, Twinkle Maheshwari, Jaymin Parikh, Simpel Saanyal, Jaikishan Agrawal

    Background: Digital therapeutics integrating continuous glucose monitoring (CGM) with personalized lifestyle coaching can enhance glycemic control in individuals with type 2 diabetes mellitus (T2DM). However, real-world evidence evaluating such multicomponent interventions—combining CGM with nutrition coaching, physiotherapy, and cognitive behavioral therapy within a unified digital platform—remains limited in South Asian populations. Objective: This study aimed to evaluate the effectiveness of an app-based lifestyle-integrated intervention program (Glycemic Lifestyle Intervention in Diabetes Empowerment–CGM; GLIDE-C) on glycemic, anthropometric, lipid profile, quality of life (QoL), and behavioral outcomes, as well as outcomes related to HEOR (health economics and outcomes research), in adults with mildly uncontrolled T2DM. Methods: A prospective observational cohort study was conducted among adults aged ≥18 years with confirmed T2DM and baseline hemoglobin A 1c (HbA 1c ) between 7.5% and 9.5%. The intervention was delivered via the Goodflip mobile app, including a 15-day CGM period and a structured analysis of glucose variations, among other clinical assessments, with follow-up on days 15, 30, and 60. The digital intervention combined CGM-guided personalized diet, exercise, and cognitive behavioral therapy plans delivered through the mobile app, supported by multidisciplinary coaching. Primary outcomes were changes in HbA 1c , fasting plasma glucose, postprandial glucose, and CGM metrics; secondary outcomes included lipid profile, anthropometric indices, QoL, and behavioral determinants of glycemic improvement. Results: Eighteen participants (mean age 49.45, SD 10.91 years; n=11, 61.1% male) completed the program. Mean HbA 1c decreased by 0.59% ( P =.05), with postprandial glucose decreasing by 25.42 mg/dL ( P =.06) and time in range increasing by 9.98%. Modest reductions, consistent with the short intervention duration, occurred in low-density lipoprotein cholesterol (−8.38 mg/dL), body fat (−1.13 kg), and waist circumference (−1.56 cm). QoL improved significantly for sleep quality ( P =.04). Improvements were also observed for motivation ( P =.06), stress management ( P =.08), and mood ( P =.12), although these changes were not statistically significant. Behavioral analysis demonstrated strong associations with glycemic outcomes; all participants who reduced their consumption of energy-dense, nutrient-poor foods experienced improvements in HbA 1c , whereas those who did not reduce energy-dense, nutrient-poor intake showed less favorable outcomes. Conclusions: The novel GLIDE-C program demonstrated clinically meaningful improvements in glycemic control, behavioral outcomes, and QoL in adults with T2DM, without pharmacological modification. These findings strengthen the role of integrated, CGM-guided digital therapeutic platforms as an effective adjunct to the conventional standard of care.